As of 2007, the only other company holding LAIV vaccine rights was BioDiem of Australia.  BioDiem licensed rights to private production of the vaccine in China to Changchun BCHT Biotechnology , which also holds public rights for production in China sublicensed from the World Health Organization .  BCHT plans to market a trivalent LAIV vaccine for H1N1 flu by the end of 2016.  The BCHT flu vaccine is one of several candidates for WHO prequalification in the near future,  reflecting a shift of Chinese market priorities from a large domestic market toward export.  BioDiem has also licensed production to the Serum Institute of India , which holds exclusive licenses for production in Mexico, Argentina, Peru, South Africa, Bangladesh, Bhutan, Nepal, Pakistan and Sri Lanka, and the Government Pharmaceutical Office of Thailand. It was the first and (as of 2007) the only live attenuated vaccine for influenza available outside of Europe .  In September 2009 a LAIV intranasal vaccine for the novel H1N1 influenza virus was approved.  In 2011, the vaccine was approved by the European Medicines Agency for use in the European Union under the name Fluenz.